Scleroderma (Systemic Sclerosis) | Treatment Algorithms: Claims Data Analysis | US | 2023
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension, interstitial lung disease, and renal crisis in SSc patients underlie a high mortality rate. The treatment landscape for SSc is dominated by generics and off-label drugs to treat the wide array of SSc symptoms; only Boehringer Ingelheim’s Ofev and Roche / Genentech’s Actemra are FDA-approved to treat the indication. This report offers insights from real-world U.S. claims data into prescribing trends in SSc to help emerging players better understand current treatment practices in SSc and how to capitalize on the unmet needs in this underserved population.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
- How have Ofev and Actemra been integrated into the treatment algorithm, and what are their sources of business? What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SSc patients are treated with monotherapy versus combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Boehringer Ingelheim, Roche, GlaxoSmithKline, Bayer HealthCare, AbbVie
Key drugs: Ofev, Actemra, Esbriet, Adempas, calcium channel blockers, conventional oral immunosuppressants, corticosteroids, PDE-5 inhibitors, select other biologics (rituximab, belimumab)
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
